Gastrointestinal stromal tumor | Tumor

Cancer Sometimes Does Not See Age

March 27th 2021, 3:00pm

Article

It is difficult for anyone to receive a cancer diagnosis, but when someone who is younger than average finds out they have gastrointestinal cancer, they may face other challenges.

Getting the Gist on GIST

March 24th 2021, 1:00pm

Article

In a recent interview with CURE®, an expert from Fox Chase Cancer Center discussed gastrointestinal stromal tumors (GIST) and addressed a multitude of topics including common symptoms associated with the disease, and potential future therapies that may be beneficial for patients.

Investigational Combination Offers ‘High Hopes’ in Treating GIST

March 23rd 2021, 9:00pm

Article

Results of a preliminary clinical trial show that MK-1775 — an investigational therapy — as a single agent, or in combination with Ayvakit, may be effective in the treatment of gastrointestinal stromal tumors. However, one of the study’s authors notes that further research is needed to determine a benefit in patients.

Advanced-Stage Rare Type of Gastrointestinal Cancer More Common in Men, Associated with ‘Excellent’ 5-Year Survival Rates

January 19th 2021, 4:00pm

Article

The data in the study presented at the ASCO Gastrointestinal Cancers Symposium demonstrated that while rare, stage 4 gastrointestinal stromal tumors often spread to the liver.

Novel Artificial Intelligence Tool May Help Patients with Cancer Find, Understand Clinical Trials

January 18th 2021, 10:00pm

Article

A group of patients with gastrointestinal cancers reported that a novel artificial intelligence-based search tool made it easier for them to find and understand cancer clinical trials. The tool, according to study authors, would not only help with trial accrual, but could also help improve trial diversity.

FDA Approves Qinlock for Patients with Pretreated, Advanced GIST

May 16th 2020, 1:26am

Article

The targeted drug Qinlock, which interferes with the activity of proteins that drive gastrointestinal stromal tumor, has been approved by the Food and Drug Administration for patients with advanced disease that has progressed despite treatment with other kinase inhibitors.

What You Need to Know About the FDA's Approval of Avyakit for GIST Subgroup

January 13th 2020, 9:17pm

Article

Patients with gastrointestinal stromal tumors have a new targeted therapy that looks to tackle secondary mutations after it showed a strong response rate in the clinic.

FDA Approves Ayvakit for the Treatment of Certain Patients with Gastrointestinal Stromal Tumor

January 10th 2020, 3:29am

Article

The Food and Drug Administration approved Ayvakit for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumor who exhibited a platelet-derived growth factor receptor alpha exon 18 mutation.

Hitting a Target in Gastrointestinal Stromal Tumors

August 2nd 2017, 8:23pm

Article

How zeroing in on the mutation in gastrointestinal stromal tumors is adding years to patients’ lives

Collaboration Lays the Groundwork for Breakthroughs in GIST

January 29th 2017, 10:33pm

Article

The Life Raft Group, a patient advocacy organization, is teaming up with research organizations to hopefully find the next wave of treatment for patients with gastrointestinal stromal tumors.